UNSPSC 51362005: Flurazepam dihydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG.

Most nations, for tariff and trade purposes, schedule flurazepam dihydrochloride under HS 29339190. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.CL.

UNSPSC 51362005 Flurazepam dihydrochloride is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though recent opportunities tagged with this code show minimal direct activity for the specific drug itself. Instead, state and local bodies are acquiring broad pharmaceutical portfolios—generic multi-source drugs, over-the-counter products, naloxone, and drug deactivation systems—through competitive procurement vehicles that bundle medications and related health supplies. Issuing bodies include state health and human services departments, county health authorities, and cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant consolidation mechanism through which multiple jurisdictions procure pharmaceuticals at scale; Seminole County, Florida and the Texas Health and Human Services Commission also appear in recent activity.

Recent opportunities reflect three procurement approaches: the MMCAP generic multi-source pharmaceuticals RFP (response deadline March 26, 2026, covering Minnesota and Oregon through authorized wholesalers), Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023, requiring annual quantities of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries to Sanford, Florida), and the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (response deadline April 3, 2026, exploring alternative procurement models outside traditional pharmacy benefit managers). Geographic activity spans Florida, Minnesota, Oregon, and Texas. Vendors pursuing pharmaceutical contracts through state and local channels should expect compliance with Drug Supply Chain Security Act (DSCSA) requirements, Good Manufacturing Practices (cGMP) certification, substantial general liability and professional liability insurance coverage, and price competition heavily weighted in evaluation—MMCAP weights price competitiveness at 75 percent of award decisions.